R-014: WHO clinical treatment guideline for tobacco cessation in adults
| Field | Value |
|---|---|
| Research ID | R-014 |
| Authors | World Health Organization |
| Year | 2024 |
| Journal / publisher | World Health Organization, Geneva (first-ever clinical guideline on tobacco cessation) |
| DOI | Not applicable |
| PMID | Not reported |
| ISBN | 9789240096431 |
| Research type | Clinical Guideline (GRADE-based) |
| Evidence strength | Strong |
| Population | Adults using any tobacco product (cigarettes, waterpipes, smokeless, cigars, heated tobacco) |
| Intervention | Behavioural support from health workers, digital interventions, pharmacotherapy (varenicline, NRT, bupropion, cytisine) |
| Comparator | Usual care / no support |
| Last verified | 2026-10-04 |
Main question
Which behavioural and pharmacological interventions should health systems offer adults who want to quit tobacco?
Main findings
Recommends a combination of behavioural support and pharmacotherapy; recommends varenicline, NRT, bupropion and cytisine as effective medications; recommends brief advice and digital tools; covers smokeless tobacco users.
Limitations
Implementation depends on national regulatory access and affordability; e-cigarette recommendations are limited by the current evidence base.
Why this record matters
The current global reference for cessation treatment; also the anchor for the Guidelines section.
Related topics
Guidelines; Quit Methods; Quit Smoking Medications